TO THE EDITOR: Joynt and colleagues (1) make an important and useful contribution to our knowledge about the role that public reporting can play in improving health care. However, wider experience with public reporting efforts suggests that we should question the overriding tenor of their article and its suggestion that public reporting of mortality data dampens the rate of change.
IN RESPONSE:
We share Drs. Lé vesque and Sutherland's conviction that public reporting has merit above and beyond its potential contribution to such clinical outcomes as mortality rates. On the one hand, it may improve consumer confidence in the health care system; allow hospital leaders to compare their own performance with local or national norms; and help drive improvements in care delivery that, although they do not translate to improvements in 30-day mortality rates, may nevertheless be highly beneficial. On the other hand, public reporting may be associated with substantial costs, including the administrative burden for hospitals; risk aversion for clinicians practicing under it (1); and gaming of the system that may make public reports suboptimally reflective of the true quality of care (2, 3) .
Drs. Lé vesque and Sutherland also suggest that public reporting is associated with improvements that are systemwide rather than condition-specific and that, therefore, public reporting for any condition leads to improvements for all conditions. Our finding that the overall rate of improvement in mortality did not accelerate for either reported or nonreported conditions after the initiation of national mandatory public reporting suggests that this phenomenon is probably not a major driver of outcomes overall. However, we cannot exclude the possibility that, for individual hospitals, public reporting spurred improvement either for specific conditions or hospital-wide. Other temporal trends also may have masked the beneficial effect of public reporting during the study period.
To say that what can't be measured can't be improved has nearly become a truism. Certainly our findings should not be construed to imply that measuring and reporting outcomes have no value-the value of such interventions can be assessed in many ways, and we examined only 1. Drs. Lé vesque and Sutherland are correct that public reporting has many potential objectives beyond the reduction of 30-day mortality. However, we do believe that our study suggests that it is probably not a powerful driver of improvements in
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Comparing Use of Low-Value Health Care Services Among U.S. Advanced Practice Clinicians and Physicians TO THE EDITOR: Mafi and colleagues (1) aim to compare the use of potentially low-value health care services among advanced practice clinicians (APCs) and physicians in the management of common conditions in the primary care setting. They found that APCs and physicians provide an equal amount of these services, dispelling physicians' perceptions that APCs provide lower-value care than physicians for such conditions (2) .
The French health care system also faces a looming shortage of care providers (3). This issue is very important for us as emergency physicians because, as in the United States (4), many patients who are unable to obtain timely outpatient care often seek care in emergency departments (EDs). This phenomenon is associated with decreased ED performance as well as decreased staff and patient satisfaction (5) . Thus, we congratulate the authors for this valuable study. Applying these concepts of flexibility may help clinicians and administrators think differently about their workflow and provide new insights into managing issues of cost, workflow, and care in the ED. It would be interesting to know what the authors think about using APCs to decrease overcrowding in the ED and thus to improve quality in this setting. TO THE EDITOR: I read Mafi and colleagues' article (1) with interest. It comes as little surprise that, with regard to treating such simple conditions as head colds, primary care providers and APCs provide equal amounts of low-quality health care. It doesn't take much training or skill to diagnose a self-limited viral infection. Doing the right thing doesn't require professional training-it requires the will to stick to one's professional guns and refuse to hand out a placebo regimen of antibiotics (or radiographs). So, perhaps this study should be titled "Both Primary Care Providers and APCs Fail the Test of Giving Patients What They Want, Not What They Need."
I would be interested to see a study of overall medical costs (and outcomes) of patients randomly assigned to seeing APCs or primary care providers for any and all conditions for a given period. If there is really no value in spending roughly 16 times the number of hours in training, then medical schools and residency programs need to have a fundamental rethink. 
Michael Kelley, MD

IN RESPONSE:
We agree with Dr. Claret and colleagues that ED overcrowding is an important public health concern and that integrating APCs into the clinical workflow in the ED may offer a solution. Although most research comparing APCs with physicians has focused on the primary care setting, few high-quality studies that we are aware of have evaluated the quality and efficiency of emergency care provided by APCs. One systematic review (that included 3 randomized trials) found that adding a nurse practitioner to see patients in the ED with minor conditions improved patient satisfaction and wait times with a negligible effect on the quality of care, which seems to be consistent with our findings in the primary care setting (1) . Another systematic review concluded that physician assistants and physicians provide similar quality of care, and 1 study found that ED wait times and workflow improved by adding physician assistants; however, the cited studies were generally limited in scope and none was a randomized trial (2) . Furthermore, 1 observational study cautions that APCs without supervision provide inferior emergency asthma care compared with APCs under physician supervision and physicians alone (3) . Although more research and careful monitoring is required, integrating APCs into team-based emergency care might be a reasonable strategy to improve workflow and reduce ED overcrowding.
We agree with Dr. Kelley that our findings cannot be generalized to support the notion that APCs and physicians generally deliver equivalent care. Although other research supports the idea that APCs provide similar quality of care for routine, protocol-driven conditions (4), we lack data on whether APCs and physicians do so for patients with more complicated presentations. These more complex patients might benefit from the additional training and expertise of a physician, but research is required to answer this question definitively. In the absence of further data on complex patients, we believe that the evidence supports expanding the role of APCs in team-based primary care for seeing patients with routine and protocol-driven conditions much like those that we studied. Such a change may enable physicians to practice at the top of their license by, for example, evaluating challenging diagnostic dilemmas, triaging potentially lifethreatening presentations, and managing complex patients with multiple chronic comorbidities. Ultimately, we believe that integrating APCs into team-based primary care models may greatly improve the quality and value of health care delivery in the United States (5) . The Fight Against Multidrug-Resistant Bacteria TO THE EDITOR: Deak and colleagues' (1) thorough review of progress toward treatment of multidrug-resistant bacteria is of great interest. Few industry-directed antibiotic trials require strategies to improve host immunity and defense or physical and chemical bacterial characteristics, such as acidification of the urine. Assessment of end points in most trials remains nebulous, as Deak and colleagues elucidate. We are curious whether the authors have an opinion on studies reporting a potentiator role for generically available calcium-channel blockers. We are aware of publications on multidrug-resistant malaria (2), schistosomiasis, tuberculosis (3), and bacteria (4). However, we have not seen any results that have answered questions raised by our article on diabetic recipients of renal allografts from nonliving donors treated with calcineurin inhibitors who had superior outcomes in terms of sepsis (5) .
It is currently in industry's best interest to develop medications for wider indications but in society's best interest to do so for the more focused purpose of effective disease treatment. We seem to be successfully fostering a system that recapitulates past antibiotic development efforts, finding "new" compounds that are "not inferior to" what we already have. Financial incentives and sophisticated statistical methods may be helpful; however, the effort to develop antibiotics effective against resistant organisms seems unlikely to achieve its goals if we do not focus on the root cause of the problem-that is, multidrug resistance. Inappropriate use of antibiotics is clearly an issue that we must address. Multidrug resistance does not occur because bacteria are cunning but rather because we are not. Incentives should be aligned to overcome pathogenic multidrug resistance in selected instances and avoid inappropriate misuse (that is, extension to livestock for financial gain).
The current time from animal testing to drug approval for widespread use could be shortened by authorizing limited use only by the Centers for Disease Control and Prevention in appropriate instances. It would be relatively easy for the U.S. Food and Drug Administration (FDA) to provide further guidance to directly focus trials to address societal needs. Although bacterial resistance in urban U.S. hospitals is a source of anxiety, improved therapy at an affordable cost for drugresistant tuberculosis, schistosomiasis, and malaria is of a higher order of urgency because of the magnitude of the population at risk.
TO THE EDITOR:
Deak and colleagues (1) raise doubts about the value of recent FDA-approved antibiotics. To the contrary, these approvals-enabled by innovative study design and regulatory guidance-represent meaningful progress for patients and public health through restoration of evidence-based, feasible antibacterial drug development. Asserting that antibacterial drug development should require "demonstrated superiority" represents a fundamental misunderstanding of societal and drug development issues. Superiority designs require delaying development until resistant bacteria are highly prevalent, a time when substantial patient harm has occurred.
Since 2010, the FDA has approved 6 of the 10 systemically available antibiotics highlighted in the Infectious Diseases Society of America's 10 × '20 Initiative (2). Among 3 agents for acute bacterial skin and skin structure infections, 1 was efficacious with a shortened duration of therapy of 6 versus 10 days, thereby supporting antimicrobial stewardship; the other 2 require much less frequent dosing than vancomycin. The gram-negative active drugs address important antibiotic-resistant infections. Initially studied for complicated urinary tract and intra-abdominal infections, both have advanced to studies in patients with hospital-acquired pneumonia.
Antibacterial drugs are usually studied in noninferiority trials. In 2010, the FDA asked the Foundation for the National Institutes of Health to develop "reliable, well-defined and clinically relevant endpoints for non-inferiority trials in [community-acquired bacterial pneumonia] and [acute bacterial skin and skin structure infections]" (3). Work informing new FDA guidances contributed to the approval of these 3 new agents for acute bacterial skin and skin structure infections plus initiation of recent studies of community-acquired bacterial pneumonia.
Deak and colleagues' critique ignores the ethical and practical reality that studies of new antibiotics in serious infections must generally be designed to avoid a finding of superior efficacy. These trials must be conducted in infections for which efficacious and safe comparator regimens exist. Superiority of an investigational antibiotic over a modern, properly dosed comparator antibiotic is unlikely to be observed when the pathogen is susceptible to both agents (4, 5) .
In the hopefully infrequent epidemiologic circumstances when a superiority trial might be possible, enrollment is highly difficult and the opportunity may close midtrial should another drug be approved that changes the standard of care (5) . Demonstration of statistical superiority of a new antibiotic requires substantial numbers of patients infected with a resistant pathogen, meaning that the antibiotic development process would have already failed patient needs. Such a public health crisis is unacceptable.
The necessarily iterative process of regulatory science will continue. Meanwhile, misunderstandings about the scientific and regulatory evaluation of antibiotics must be corrected. Society is owed a robust, diverse, renewable pipeline of antibiotics that can be developed in advance of widespread bacterial resistance through scientifically sound, feasible, and ethical clinical trials.
IN RESPONSE:
We agree with Drs. Weinrauch and D'Elia's call for greater emphasis on making currently available products more effective through host modulation and improvements in stewardship. Although we do not have specific insight into the potentiator role of calcium-channel blockers, we believe that funders should prioritize limited resources by supporting investigations of scientifically plausible and cost-effective interventions.
Of course, resistance can develop even when antibiotics are optimally used, necessitating a vibrant antibiotic pipeline. We agree with Dr. Boucher and colleagues that noninferiority designs for such products can benefit patients. However, we believe that recognizing the limits of these trials is also important, particularly for patients with multidrug-resistant infections.
Noninferiority studies are traditionally done in patients with effective therapeutic options and treatable disease and are intended to show that the experimental product is not inferior at a certain acceptable level compared with the standard of care (usually approximately 10%). These designs therefore do not directly address whether an investigational product shows improved effectiveness in patients with resistant disease. When new antibiotics studied in noninferiority trials are then used in patients with resistant pathogens, they may actually show worse clinical outcomes than in patients with susceptible pathogens (1) .
By contrast, superiority trials are appropriate for patients with resistant infections and no therapeutic options and do not necessarily require large numbers of participants (2) . This design also may facilitate enrollment, because superiority trials often lack restrictions on enrollment (for example, excluding prior effective therapy) that are necessary for noninferiority trials. Although superiority trials for some resistant infections may pose enrollment challenges (3), stakeholders are working to design and fund new clinical trial networks and develop rapid diagnostics to improve the process (4).
Dr. Boucher and colleagues question the ethics of superiority trials because such designs expose some patients to potentially less effective older drugs. However, noninferiority trials raise similar concerns about appropriate selection of research participants and balancing risks and benefits. In our sample, 7 of the 8 drugs were approved on the basis of tests using noninferiority designs and 3 showed negative estimates within the noninferiority margin.
Our article identified many limitations among recently approved antibiotics apart from the design of their pivotal trials, including lack of innovation in mechanism of action and lack of evidence of clear effects on patient-centered outcomes. Future antibiotics will need to have improvements in all of these variables to address the rise of resistance.
